
    
      CAR-T has stronger effect of anti-tumor capacity. While people have been able to control the
      clinical complications now, so conducting CAR-T clinical trials has a strong demand and
      value. This study aims to evaluate the safety and efficacy of CD19-CART in treating
      refractory or recurrent ALL.
    
  